Between them, Royal Philips and Thermo Fisher have been driving a mini M&A spree in the medical technology sector, snapping up three companies in the last few weeks.
Shares in Agios Pharma ticked upwards after the FDA awarded breakthrough status to a companion diagnostic to vorasidenib, its experimental drug for brain cancer.
AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceut